

Proton NMR investigations on 6-alkylamino-2-alkylthioadenosine derivatives

Hongguang Du,^a Qiwen He,^a Ning Chen,^a Jiaxi Xu,^a Fei Chen^b and Guocheng Liu^{b*}

Introduction

Purine nucleosides have taken up an important role in living systems. Not only are purines the basic subunits of the nucleic acids, but they also interact with enzymes and other proteins as components of cofactors and signal molecules.^[1–3] Their modified nucleosides and nucleotides are very important classes of compounds used in the therapy of a wide variety of diseases, because they can act as antiviral,^[4] antitumor^[5] and antimicrobial agents.^[6] Purine nucleosides in which the alkylthio group at C-2 position and the alkylamino substituent at C-6 position typically excel in antiplatelet activities^[7–13] (Fig. 1). So the synthesis and characterization of the modified purine nucleosides have attracted the attention of our and other many scientific teams.^[14–18]

The distribution of electrons around the purine skeleton affects not only its chemical properties and reactivity but also the nuclear magnetic resonance (NMR) parameters. The nature of the substituent is reflected in the NMR chemical shifts and nuclear spin–spin coupling constants, which makes NMR spectroscopy an excellent tool for investigating and interpreting the structure, reactivity and intermolecular interactions in terms of the electron distribution.^[19,20] The use of proton NMR spectroscopy could be a helpful tool to achieve it. Recently, we have published a complete analysis of proton NMR data for 6-alkylamino-2-alkylthioadenosine derivatives, and we observed that two protons of SCH₂ at C-2 of purine skeleton are split into one/two 'dt' or 'dq' coupling peaks, rather than canonical 't' or 'q' peaks,^[9] but the reason is not clear.

To reveal the general behaviors of the chemical shifts signals of SCH₂ group depending on the configuration for SCH₂-containing adenosine derivatives, two series of 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines and 6-alkyl(aryl)amino-2-alkylthiopurines were synthesized, and their proton NMR spectroscopic properties were described.

Experiment

The proton and carbon NMR spectra were recorded with Varian Mercury plus 200 (200 MHz), Varian Mercury plus 300 (300 MHz), Bruker 400 AMX (400 MHz) or Bruker 600 AMX (600 MHz) spectrometer in CDCl₃ or DMSO-*d*₆ as the solvent with tetramethylsilane as an internal standard at 298 K.

Chemical shifts are reported in ppm on δ scale, and signals are expressed as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br s (broad).

Results and discussion

The 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines (**5a–l**) and 6-alkyl(aryl)amino-2-alkylthiopurines (**5m–o**) were synthesized according to our previous reported procedures,^[9,10] which were outlined in Scheme 1. 6-Alkyl(aryl)amino-2-alkyl(aryl)thioadenosines (**5a–l**) was synthesized from the starting material guanosine (**1**) via acetylation, chlorination, diazotization–alkanethiolation and ammonolysis. 6-Alkyl(aryl)amino-2-alkylthiopurines (**5m–o**) were prepared by treating with 2-bromoethyl acetate, diazotization–alkanethiolation and ammonolysis from 2-amino-6-chloropurine (**6**). All of the 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines and 6-alkyl(aryl)amino-2-alkylthiopurines derivatives, except **5a**, **5c**, **5e**, **5k** and **5m**, are new compounds (Table 1).

Analysis of the proton NMR data of 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines (Table 2), we found that NH at C-6 of purine skeleton is a broad peak around 8.20 ppm, C-8 hydrogen is close to 8.50–7.90 ppm as a single peak; and then the chemical shifts of the nine protons in ribose are assigned in the region of 5.9–3.4 ppm. The SCH₂ at C-2 is assigned in the region of 3.10–2.90 ppm. However, if the substituent is SCH₃, the chemical shift is assigned at 2.5 ppm, which is often buried in the signals (two methyl peaks) of deuterated dimethylsulfoxide (DMSO-*d*₆) when it was used as the solvent (see ref. 9, compounds 5b₁, 5b₇, 5b₁₀, 5b₁₆ and 5b₂₀).

As can be seen from the proton NMR spectrum of 6-chloro-2-propylthio-9-(2',3',5'-tri-*O*-acetyl- β -*D*-ribofuranosyl)-9*H*-purine (**4b**, Fig. 2) in DMSO-*d*₆ solution, the two proton signals of SCH₂ were not shown as canonical 't' peak, but as 'dt' coupling peak, and the

* Correspondence to: Guocheng Liu, The CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China. E-mail: liuguocheng@big.ac.cn

a State Key Laboratory of Chemical Resource Engineering, Department of Organic Chemistry, College of Science, Beijing University of Chemical Technology, Beijing 100029, China

b The CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China





Figure 1. Chemical structures and numberings of 6-alkylamino-2-alkylthio-9-substituted purines.

assignment of the $J(\text{SCH}_2)$ values was 13.1 and 7.3 Hz. To our surprise, the multiplicity of CH_2 contiguous to sulfur (S) of compounds **5a**, **5c**, **5e**, **5k**, **5j** and **5l** in $\text{DMSO}-d_6$ is not the 't' or 'q' peaks, either, but the 'dt' or 'dq' coupling peaks, and the assignment of the $J(\text{SCH}_2)$ values was still 13.1 and 7.3 Hz (Fig. 2). The results demonstrate that two protons of SCH_2 are diastereomerism and their chemical shifts non-equivalence. Each of protons signal is split twice, which are first coupled each other as doublet peaks, and then is split by their adjacent substituent CH_2 or CH_3 into triplet or quartet peaks. However, when the ^1H NMR spectrum was recorded in CDCl_3 , the two protons of SCH_2 were split into two separated 'dt' or 'dq' coupling peaks and the $J(\text{SCH}_2)$ values were still 13.1 and 7.3 Hz (Fig. 3). It indicates

Table 1. Chemical structures of 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines (**5a-l**) and 6-alkyl(aryl)amino-2-alkylthiopurines (**5m-o**)

Entry	Compound 5	R	R ¹	R ²	R ³
1	5a ^[9]	<i>n</i> -Pr	$\text{CH}_2(\text{CH}_2)_4\text{CH}_3$	H	R ⁴
2	5b	<i>i</i> -Pr	$\text{CH}_2(\text{CH}_2)_4\text{CH}_3$	H	R ⁴
3	5c ^[9]	<i>n</i> -Bu	$\text{CH}_2(\text{CH}_2)_4\text{CH}_3$	H	R ⁴
4	5d	<i>n</i> -Bu	$\text{CH}_3\text{OCH}_2\text{CH}_2$	H	R ⁴
5	5e ^[9]	Et	<i>c</i> -C ₆ H ₁₁	H	R ⁴
6	5f	<i>n</i> -Pr	<i>p</i> -MePhCH ₂	H	R ⁴
7	5g	<i>n</i> -Bu	<i>p</i> -MePhCH ₂	H	R ⁴
8	5h	<i>n</i> -Bu	<i>p</i> -MeOPhCH ₂	H	R ⁴
9	5i	CH_2Ph	<i>p</i> -MeOPhCH ₂ CH ₂	H	R ⁴
10	5j	<i>n</i> -Pr	$\text{CH}(\text{CH}_3)\text{Ph}$	H	R ⁴
11	5k ^[9]	Et	<i>n</i> -Bu	<i>n</i> -Bu	R ⁴
12	5l	<i>n</i> -Pr	<i>n</i> -Bu	<i>n</i> -Bu	R ⁴
13	5m ^[10]	Et	<i>n</i> -Pr	H	R ⁵
14	5n	<i>n</i> -Bu	PhCH_2CH_2	H	R ⁵
15	5o	<i>n</i> -Pr	<i>n</i> -Bu	<i>n</i> -Bu	R ⁵



Scheme 1. Synthesis of 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines and 6-alkyl(aryl)amino-2-alkylthiopurines.

Table 2. ¹H NMR chemical shifts (ppm) for 6-alkyl(aryl)amino-2-alkyl(aryl)thioadenosines (**5**)

Compound 5	H-8	NH-6	H-1'	OH-2'	OH-3'	OH-5'	H-2'	H-3'	H-4'	H-5' _a	H-5' _b	SCH ₂ -2
5a ^[9]	8.19	7.92	5.80	5.37	5.13	5.06	4.58	4.13	3.92	3.64	3.53	3.07 3.05
5c ^[9]	8.19	7.90	5.80	5.37	5.12	5.04	4.58	4.12	3.92	3.64	3.53	3.09 3.08
5d	8.23	7.88	5.81	5.43	5.18	5.08	4.58	4.12	3.92	3.63	3.56	3.07 3.08
5e ^[9]	8.21	7.73	5.81	5.41	5.18	5.07	4.58	4.13	3.92	3.64	3.53	3.07 3.06
5f	8.23	8.47	5.81	5.40	5.15	5.05	4.59	4.12	3.92	3.64	3.53	2.99
5g	8.24	8.49	5.81	5.43	5.18	5.08	4.60	4.13	3.92	3.65	3.53	3.02
5h	8.23	8.47	5.81	5.42	5.17	5.07	4.58	4.13	3.92	3.60-3.43		3.03
5j	8.24	8.42	5.80	5.39	5.14	5.04	4.56	4.12	3.92	3.63	3.52	2.98 2.95




Figure 2. The SCH₂ splitting in ¹H-NMR spectra of compounds **4b**, **5a**, **5c**, **5j**, **5k** and **5l** in DMSO-*d*₆.




Figure 3. The SCH₂ splitting in $^1\text{H-NMR}$ spectra of compounds **5e**, **5k**, **5j** and **5l** in CDCl_3 .




Figure 4. The SCH₂ splitting in $^1\text{H-NMR}$ spectra of compounds **5m**, **5n** and **5o**.

that the SCH₂ was also split into 'dt' or 'dq' coupling peaks, but as two separate parts.

The four chiral carbons in ribose, which connected with the 9-N of the purine skeleton, especially the 1'-carbon, the nearest chiral center, although there are seven chemical bonds between the SCH₂ and 1'-carbon, generate a long-range chiral effect resulting the two protons of SCH₂ chemical shift non-equivalence. However, when the non-chiral carbon-substituent at the 9-N of the purine skeleton, the two protons in SCH₂ were normally split into a 't' or 'q' peaks, rather than two 'dt' or 'dq' peaks (**5m-o**, Fig. 4). This proves that the four chiral carbons at the 9-N of purine skeleton result the two protons of SCH₂ diastereomerism, their chemical shift non-equivalence and split into two 'dt' or 'dq' coupling peaks.

Further analysis of the ¹H-NMR of the target compounds **5a-l**, suggesting that there is existence of solvent effect between CDCl₃ and DMSO-*d*₆. Such as the chemical shifts of NH and SCH₂, the NH chemical shift of compound **5j-l** in CDCl₃ was around 7.53 ppm but moved to 8.41 ppm in DMSO-*d*₆ (Figs. 2 and 3). It was assumed that a hydrogen bond was generated between solvent (CDCl₃) and the sample. The SCH₂ was split into two separated moieties in CDCl₃ as 'dt' coupling peaks but in DMSO-*d*₆ occurs in an integral for the coupling peaks (Fig. 2 and Fig. 3). In addition to the proton NMR data of SCH₂ and NH, the peaks of other groups also have a little change, but not very obviously.

Conclusions

In summary, the preparation and proton NMR spectroscopic characterization of several novel SCH₂-containing adenosine derivatives were described. The ¹H-NMR spectra of 6-alkylamino-2-alkylthioadenosine derivatives suggest that the two protons in the SCH₂ are diastereomerism, their chemical shifts non-equivalence and split into two 'dt' or 'dq' coupling peaks. However, the two protons of SCH₂ of 9-acetoxyethyl-6-alkylamino-2-alkylthiopurine derivatives are normally split into a canonical 't' or 'q' peak. This proves that the chiral carbons at the 9-N of purine skeleton have a long-range chiral effect on the two diastereotopic protons of SCH₂.

Acknowledgement

This work was supported in part by the National Natural Science Foundation of China (project no. 21272022).

References

- [1] G. M. Blackburn, M. J. Gait, D. Loakes, D. Williams, *Nucleic Acids in Chemistry and Biology*, RSC, Cambridge, **2008**, pp. 13–75.
- [2] M. Legraverend. *Tetrahedron* **2008**, *64*, 8585–8603.
- [3] A. Manvar, A. Shah. *Tetrahedron* **2013**, *69*, 8105–8127.
- [4] M. Egli, P. Herdewijn, *Chemistry and Biology of Artificial Nucleic Acids*, Wiley, New York, **2012**, pp. 187–258.
- [5] N. R. Kode, S. Phadtare. *Molecules* **2011**, *16*, 5840–5860.
- [6] J. N. Kim, K. F. Blount, I. Puskarz, J. Lim, K. H. Link, R. R. Breaker. *ACS Chem. Biol.* **2009**, *4*, 915–927.
- [7] A. H. Ingall, J. Dixon, A. Bailey, M. E. Coombs, D. Cox, J. I. McNally, S. F. Hunt, N. D. Kondon, B. J. Teobald, P. A. Willis, R. G. Humphries, P. Leff, J. A. Clegg, J. A. Smith, W. Tomlinson. *J. Med. Chem.* **1999**, *42*, 213–220.
- [8] B. Springthorpe, A. Bailey, P. Barton, T. N. Birkinshaw, R. V. Bonnert, R. C. Brown, D. Chapman, J. Dixon, S. D. Guile, R. G. Humphries, S. F. Hunt, F. Ince, A. H. Ingall, I. P. Kirk, P. D. Leeson, P. Leff, R. J. Lewis, B. P. Martin, D. F. McGinnity, M. P. Mortimore, S. W. Paine, G. Pairedeau, A. Patel, A. J. Rigby, R. J. Riley, B. J. Teobald, W. Tomlinson, P. J. Webborn, P. A. Willis. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6013–60138.
- [9] G. Liu, J. Xu, N. Chen, S. Zhang, Z. Ding, H. Du. *Eur. J. Med. Chem.* **2012**, *53*, 114–123.
- [10] Q. He, H. Du. *Chin. J. Org. Chem.* **2012**, *32*, 1678–1683.
- [11] C. Pan, X. Wei, J. Ye, G. Liu, S. Zhang, Y. Zhang, H. Du, Z. Ding. *PLoS One* **2012**, *7*, e40451. doi:10.1371/journal.pone.0040451.
- [12] L. Hu, Z. Fan, H. Du, R. Ni, S. Zhang, K. Yin, J. Ye, Y. Zhang, X. Wei, X. Zhang, P. L. Gross, S. P. Kunapuli, Z. Ding. *Thromb. Haemost.* **2011**, *106*, 1204–1214.
- [13] S. Zhang, L. Hu, H. Du, Y. Guo, Y. Zhang, H. Niu, J. Jin, J. Zhang, J. Liu, X. Zhang, S. P. Kunapuli, Z. Ding. *Thromb. Haemost.* **2010**, *104*, 845–857.
- [14] A. Kovalovs, I. Novosjolova, E. Bizdena, I. Bizane, L. Skardziute, K. Kazlauskas, S. Jursenas, M. Turks. *Tetrahedron Lett.* **2013**, *54*, 850–853.
- [15] G. R. Qu, H. L. Zhang, H. Y. Niu, Z. K. Xue, X. X. Lv, H. M. Guo. *Green Chem.* **2012**, *14*, 1877–1879.
- [16] S. M. Devine, P. J. Scammells. *Eur. J. Org. Chem.* **2011**, *6*, 1092–1098.
- [17] S. M. Devine, A. Gregg, H. Figler, K. McIntosh, V. Urmaliya, J. Linden, C. W. Pouton, P. J. White, S. E. Bottle, P. J. Scammells. *Bioorg. Med. Chem.* **2010**, *18*, 3078–3087.
- [18] R. Narukulla, D. E. Shuker, V. Ramesh, Y. Z. Xu. *Magn. Reson. Chem.* **2008**, *46*, 1–8.
- [19] S. Standara, K. Maliňáková, R. Marek, J. Marek, M. Hocek, J. Vaara, M. Straka. *Phys. Chem. Chem. Phys.* **2010**, *12*, 5126–5139.
- [20] E. Procházková, L. Cechová, P. Jansa, M. Dračinský. *Magn. Reson. Chem.* **2012**, *50*, 295–298.

Supporting information

Additional supporting information may be found in the online version of this article at the publisher's website.